The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin

• The podium presentation will be in a session of ‘Selected
  Abstracts of Excellence’
• Top line data from Can-Fite Phase II study of Namodenoson in the
  treatment of NAFLD and NASH expected H2 2019
• Preclinical data show improved liver function,
  anti-inflammatory, anti-fibrotic, anti-steatotic effects

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite
BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology
company with a pipeline of proprietary small molecule drugs that address
cancer, liver and inflammatory diseases, announced today that it has
been selected for a podium presentation in a session of ‘Selected
Abstracts of Excellence’ titled, “Namodenoson anti-NAFLD/NASH Activity
is Mediated via De-regulation of the Wnt/β-catenin Pathway” at the 2^nd
Annual International Conference on Fatty Liver (ICFL
2019) in Berlin, Germany which takes place on June 27-29, 2019.
Can-Fite CEO Dr. Pnina Fishman will deliver the presentation at 15:50 on
June 28, 2019.

ICFL 2019 is focused on the clinical needs and best practices for
diagnosing and treating fatty liver disease to address the challenges
and long-term effects of this disease. ICFL 2019 will feature leading
experts across the relevant fields to educate and foster knowledge
exchange.

“We look forward to presenting data on Namodenoson at this gathering of
the world’s thought leaders on fatty liver disease. Our compelling
preclinical findings with NASH experimental models as well as our Phase
II study design will be discussed. Top line results from our Phase II
study in nonalcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) are expected in the second half of 2019,” stated
Dr. Fishman.

The Phase II NASH study is currently ongoing in Israel and aimed at the
enrollment of 60 patients who suffer from NAFLD/NASH with evidence of
active inflammation. The patients are treated twice daily with 12.5 or
25 mg of oral Namodenoson vs. placebo for 12 weeks. The primary end
points of the Phase II study have been recently amended and include the
anti-inflammatory effect of the drug, as determined by ALT blood levels,
and the percentage of liver fat, as measured by MRI-PDFF (proton density
fat fraction). The Company anticipates the data release in the second
half of 2019.

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high
affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated as a second line treatment for
hepatocellular carcinoma, with a recently completed Phase II trial and
planned Phase III trial in this indication. The drug is currently in an
ongoing Phase II trial as a treatment for non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in normal
cells. This differential effect accounts for the excellent safety
profile of the drug.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets in
the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company’s lead drug candidate, Piclidenoson, is currently in Phase
III trials for rheumatoid arthritis and psoriasis. Can-Fite’s liver
cancer drug, Namodenoson, recently completed a Phase II trial for
hepatocellular carcinoma (HCC), the most common form of liver cancer,
and is in a Phase II trial for the treatment of non-alcoholic
steatohepatitis (NASH). Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat other
cancers including colon, prostate, and melanoma. CF602, the Company’s
third drug candidate, has shown efficacy in the treatment of erectile
dysfunction in preclinical studies and the Company is investigating
additional compounds, targeting A3AR, for the treatment of sexual
dysfunction. These drugs have an excellent safety profile with
experience in over 1,000 patients in clinical studies to date. For more
information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts,
business, financial condition, results of operations, strategies or
prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally
or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as “believe,” “expect,” “intend,” “plan,”
“may,” “should” or “anticipate” or their negatives or other variations
of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or with
the approval of one of Can-Fite’s authorized executive officers.
Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that
could cause Can-Fite’s actual results to differ materially from any
future results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite’s actual activities or results to
differ materially from the activities and results anticipated in such
forward-looking statements. Factors that could cause our actual results
to differ materially from those expressed or implied in such
forward-looking statements include, but are not limited to: our history
of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working capital
needs; the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into clinical
trials or to successfully complete our preclinical studies or clinical
trials; our receipt of regulatory approvals for our product candidates,
and the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic partnerships
and other corporate collaborations; the implementation of our business
model and strategic plans for our business and product candidates; the
scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our
ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our
industry; statements as to the impact of the political and security
situation in Israel on our business; and risks and other risk factors
detailed in Can-Fite’s filings with the SEC and in its periodic filings
with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by
economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events or
otherwise.

Contacts

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114